The objective of the present study is optimization of valsartan SR floating tablet formulation by 22 factorial design. SR floating tablets of valsartan (80 mg) were formulated employing HPMCK100M as matrix forming polymer, sodium bicarbonate as gas generating agent and beeswax and ethyl cellulose as floating enhancers. Valsartan is an orally active anti-hypertensive drug, majorly absorbed from stomach and upper small intestine. Formulation of sustained release floating tablets of valsartan is needed because of its poor oral bioavailability and short biological half-life. Valsartan floating tablets were formulated as per 22 factorial design and were evaluated. Valsartan SR floating tablets prepared as per 22 factorial design were non-disinte...
Valsartan is a potent, orally active non peptide tetrazole derivative and selectively inhibits Angio...
Valsartan, an angiotensin-receptor blocker (ARB) widely prescribed in variety of cardiac conditions ...
The present study has a design to evaluate the valsartan conventional tablets by using various binde...
The objective of the present study is optimization of valsartan floating tablet formulation by 23 fa...
The objective of the present study is optimization of valsartan floating tablet formulation by 23 fa...
The purpose of the present investigation was to develop and optimize bilayered sustained release mat...
The objective of the present study is optimization of Valsartan tablet formulation employing βCD, St...
The goal of the current study is to produce a modified dose form of the hypertension drug Valsartan....
Objective: The main purpose of this study was to formulate and statistically evaluate 300 mg floatin...
The objective of the present study is optimization of losartan floating tablet formulation by 23 fac...
ABSTRACT: The immediate release tablet of antihypertensive drug Valsartan were prepared and evaluate...
Floating Drug Delivery Systems (FDDS) have a bulk density lower than gastric fluids and thus remain ...
Sustained release tablets and capsules are commonly taken only once or twice daily, compared with co...
The objective of the present study is to develop a pharmaceutically stable, cost effective and quali...
The sustained release tablets were formulated by using the combination of various release retardant ...
Valsartan is a potent, orally active non peptide tetrazole derivative and selectively inhibits Angio...
Valsartan, an angiotensin-receptor blocker (ARB) widely prescribed in variety of cardiac conditions ...
The present study has a design to evaluate the valsartan conventional tablets by using various binde...
The objective of the present study is optimization of valsartan floating tablet formulation by 23 fa...
The objective of the present study is optimization of valsartan floating tablet formulation by 23 fa...
The purpose of the present investigation was to develop and optimize bilayered sustained release mat...
The objective of the present study is optimization of Valsartan tablet formulation employing βCD, St...
The goal of the current study is to produce a modified dose form of the hypertension drug Valsartan....
Objective: The main purpose of this study was to formulate and statistically evaluate 300 mg floatin...
The objective of the present study is optimization of losartan floating tablet formulation by 23 fac...
ABSTRACT: The immediate release tablet of antihypertensive drug Valsartan were prepared and evaluate...
Floating Drug Delivery Systems (FDDS) have a bulk density lower than gastric fluids and thus remain ...
Sustained release tablets and capsules are commonly taken only once or twice daily, compared with co...
The objective of the present study is to develop a pharmaceutically stable, cost effective and quali...
The sustained release tablets were formulated by using the combination of various release retardant ...
Valsartan is a potent, orally active non peptide tetrazole derivative and selectively inhibits Angio...
Valsartan, an angiotensin-receptor blocker (ARB) widely prescribed in variety of cardiac conditions ...
The present study has a design to evaluate the valsartan conventional tablets by using various binde...